Ongoing and Planned Clinical Trials

– Please select –Ongoing / PlannedCompletedInvestigator-Sponsored Trials / Research

Ongoing

• RESMAIN – Resminostat versus placebo as maintenance therapy in cutaneous T cell lymphoma (CTCL)
• Resminostat plus S-1 in biliary tract cancer (BTC)
• SENSITIZE – Domatinostat (4SC-202) + pembrolizumab (Keytruda^®, Merck) in patients with unresectable advanced-stage melanoma refractory or non-responding to prior anti-PD-1 treatment

Planned

• EMERGE – Phase II of domatinostat (4SC-202) in combination with an anti-PD-L1 antibody in microsatellite-stable gastrointestinal tumors

RESMAIN – Resminostat versus placebo as maintenance therapy in cutaneous T‑cell lymphoma (CTCL)

NCT02953301

The pivotal RESMAIN study is a multi-national, multi-center, double-blind, randomized and placebo controlled study to evaluate resminostat for maintenance treatment of patients with advanced stage (Stage IIB‑IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy.

Back to top

Resminostat plus S-1 in biliary tract cancer (BTC)

This is a double-blind, randomized Phase II study to assess the efficacy of resminostat in combination with S-1 (experimental arm) compared to placebo in combination with S-1 (control arm) in patients with unresectable or platinum-gemcitabine combination refractory biliary tract cancer conducted by our cooperation partner Yakult Honsha.

Back to top

SENSITIZE – Domatinostat (4SC-202) + pembrolizumab (Keytruda^®, Merck) in patients with unresectable advanced-stage melanoma refractory or non-responding to prior anti-PD-1 treatment

NCT03278665

The SENSITIZE study is an open-label, multi-center, Phase Ib/II study to evaluate the combination treatment of domatinostat with the anti-PD-1 antibody pembrolizumab (Keytruda^®, Merck) in patients suffering from advanced-stage cutaneous melanoma who are refractory or non-responding to prior treatment with anti-PD-1 antibodies.

Back to top